Top

Published in:

01-04-2014 | Review Article

A Rationalized Approach to the Treatment of Patients Infected with Hepatitis B

Authors: Natravis R. Cox, Keyur Patel, Hans L. Tillmann

Published in: Molecular Diagnosis & Therapy | Issue 2/2014

Abstract

It is estimated that there are 350–400 million individuals with chronic hepatitis B virus infection (HBV) worldwide. The natural course of HBV infection is variable with a number of individuals developing no or only mild disease, while others will die from liver-associated complications if left untreated. It is estimated that 25 % of individuals with HBV infection will eventually die from the complications of HBV-associated liver disease. Several viral and host variables including hepatitis B e antigen status, HBV genotype, viral load, hepatitis B surface antigen and transaminase levels, and viral mutations have been identified as determinants of disease outcomes. The personalized approach to the treatment of chronic hepatitis B might include mere monitoring of the disease in some patients but aggressive treatment in others. Individuals who require treatment should have close monitoring to help ensure maximum medication compliance, to watch for adverse events, and to monitor virologic and biochemical responses. Therefore, management of patients with chronic HBV infection requires a practical setting to demonstrate the relevance of personalized medicine, the roles and limitations of genetic and non-genetic factors, and the risks and benefits of individualized patient care. This article provides an overview of the viral and host genetics of chronic HBV and reviews the clinical utility of serum quantitative hepatitis B surface antigen in the management of patients with chronic HBV infection.

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38.PubMedCrossRef

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis. 2004;11(2):97–107.CrossRef

Cox N, Tillmann H. Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs. 2011;16(4):713–29.PubMedCrossRef

Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–74.PubMedCrossRef

Fwu CW, Chien YC, Kirk GD, Nelson KE, You SL, Kuo HS, et al. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst. 2009;101(14):1019–27.PubMedCrossRef

Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629–38.PubMedCrossRef

Lok AS. Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? Hepatology. 2010;51(4):1107–9.PubMedCrossRef

Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34(4 Pt 1):617–24.PubMedCrossRef

Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver. 1989;9(4):235–41.PubMedCrossRef

10.

Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1994;21(4):656–66.PubMedCrossRef

11.

Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.PubMedCrossRef

12.

EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.

13.

Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology. 1983;3(5):656–62.PubMedCrossRef

14.

Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus: large-scale analysis using a new genotyping method. J Infect Dis. 1997;175(6):1285–93.PubMedCrossRef

15.

Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat. 2002;9(1):52–61.PubMedCrossRef

16.

Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.PubMedCrossRef

17.

Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139(2):483–90.PubMedCrossRef

18.

Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000;64(1):51–68.PubMedCentralPubMedCrossRef

19.

Yin J, Xie J, Liu S, Zhang H, Han L, Lu W, et al. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol. 2011;106(1):81–92.PubMedCrossRef

20.

Yuen MF, Tanaka Y, Shinkai N, Poon RT, But DY, Fong DY, et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut. 2008;57(1):98–102.PubMedCrossRef

21.

Kim JK, Chang HY, Lee JM, Baatarkhuu O, Yoon YJ, Park JY, et al. Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol. 2009;81(6):1002–8.PubMedCrossRef

22.

Liao Y, Hu X, Chen J, Cai B, Tang J, Ying B, et al. Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS ONE. 2012;7(6):e38394.PubMedCentralPubMedCrossRef

23.

Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst. 2009;101(15):1066–82.PubMedCentralPubMedCrossRef

24.

Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol. 1988;69(Pt 10):2575–83.PubMedCrossRef

25.

Norder H, Hammas B, Lofdahl S, Courouce AM, Magnius LO. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol. 1992;73(Pt 5):1201–8.PubMedCrossRef

26.

Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol. 2000;81(Pt 1):67–74.PubMed

27.

Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004;47(6):289–309.PubMedCrossRef

28.

Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol. 2009;83(20):10538–47.PubMedCentralPubMedCrossRef

29.

Suzuki Y, Kobayashi M, Ikeda K, Suzuki F, Arfase Y, Akuta N, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol. 2005;76(1):33–9.PubMedCrossRef

30.

Kobayashi M, Suzuki F, Arase Y, Akuta N, Suzuki Y, Hosaka T, et al. Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001. J Gastroenterol. 2004;39(9):844–50.PubMedCrossRef

31.

Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat. 2005;12(2):192–8.PubMedCrossRef

32.

Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology. 2002;35(5):1274–6.PubMedCrossRef

33.

Zhao H, Kurbanov F, Wan MB, Yin YK, Niu JQ, Hou JL, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis. 2007;44(4):541–8.PubMedCrossRef

34.

Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365(9454):123–9.PubMedCrossRef

35.

Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135(2):459–67.PubMedCrossRef

36.

Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136(7):2169–79 e1–4.

37.

Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antiviral Ther. 2008;13(2):211–20.

38.

Hsieh TH, Tseng TC, Liu CJ, Lai MY, Chen PJ, Hsieh HL, et al. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antiviral Ther. 2009;14(8):1157–63.CrossRef

39.

Damerow H, Yuen L, Wiegand J, Walker C, Bock CT, Locarnini S, et al. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol. 2010;82(11):1850–8.PubMedCrossRef

40.

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.PubMedCrossRef

41.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–4.PubMedCrossRef

42.

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.PubMedCrossRef

43.

Lin TM, Chen CJ, Wu MM, Yang CS, Chen JS, Lin CC, et al. Hepatitis B virus markers in Chinese twins. Anticancer Res. 1989;9(3):737–41.PubMed

44.

Mbarek H, Ochi H, Urabe Y, Kumar V, Kubo M, Hosono N, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet. 2011;20(19):3884–92.PubMedCrossRef

45.

Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet. 2009;41(5):591–5.PubMedCrossRef

46.

Thio CL, Thomas DL, Karacki P, Gao X, Marti D, Kaslow RA, et al. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol. 2003;77(22):12083–7.PubMedCentralPubMedCrossRef

47.

Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med. 1995;332(16):1065–9.PubMedCrossRef

48.

Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol. 1997;26(3):503–7.PubMedCrossRef

49.

Jiang YG, Wang YM, Liu TH, Liu J. Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B. World J Gastroenterol. 2003;9(10):2221–5.PubMed

50.

Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenefelde KH, Rittner C. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol. 1998;111(3):579–82.PubMedCentralPubMedCrossRef

51.

Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection: association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol. 2005;42(4):505–10.PubMedCrossRef

52.

Thursz M, Yee L, Khakoo S. Understanding the host genetics of chronic hepatitis B and C. Semin Liver Dis. 2011;31(2):115–27.PubMedCrossRef

53.

Wu YF, Wang LY, Lee TD, Lin HH, Hu CT, Cheng ML, et al. HLA phenotypes and outcomes of hepatitis B virus infection in Taiwan. J Med Virol. 2004;72(1):17–25.PubMedCrossRef

54.

Lu LP, Liu Y, Li XW, Sun GC, Zhu XL, Wu YZ, et al. Association of polymorphisms of human leucocyte antigen -DRB1 and -DQA1 allele with outcomes of hepatitis B virus infection in Han population of north China. Zhongguo yi xue ke xue yuan xue bao Acta Academiae Medicinae Sinicae. 2006;28(2):134–42.PubMed

55.

Ahn SH, Han KH, Park JY, Lee CK, Kang SW, Chon CY, et al. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology. 2000;31(6):1371–3.PubMedCrossRef

56.

Cheng YQ, Lin JS, Huang LH, Tian DY, Xiong P. [The association of HLA-DRB1 allele polymorphism with the genetic susceptibility to liver cirrhosis due to hepatitis B virus]. Zhonghua yi xue yi chuan xue za zhi Zhonghua yixue yichuanxue zazhi. Chin J Med Genet. 2003;20(3):247–9.

57.

Correa Bde M, Lopes EP, Albuquerque Mde F, Dourado L. Association between HLA-DRB1* polymorphisms and hepatitis B infection in a Brazilian population. Rev Assoc Med Bras. 2012;58(5):537–42.PubMedCrossRef

58.

Thio CL, Carrington M, Marti D, O’Brien SJ, Vlahov D, Nelson KE, et al. Class II HLA alleles and hepatitis B virus persistence in African Americans. J Infect Dis. 1999;179(4):1004–6.PubMedCrossRef

59.

Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16(7):453–63.PubMedCrossRef

60.

Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet. 2010;42(9):755–8.PubMedCrossRef

61.

Chan KY, Wong CM, Kwan JS, Lee JM, Cheung KW, Yuen MF, et al. Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. PLoS ONE. 2011;6(12):e28798.PubMedCentralPubMedCrossRef

62.

Chan KL, Lee JM, Guan XY, Fan ST, Ng IO. High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. Cancer. 2002;94(12):3179–85.PubMedCrossRef

63.

Su WH, Chao CC, Yeh SH, Chen DS, Chen PJ, Jou YS. OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. Nucleic Acids Res. 2007;35(Database issue):D727–31.PubMedCentralPubMedCrossRef

64.

Guo X, Zhang Y, Li J, Ma J, Wei Z, Tan W, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology. 2011;53(2):422–8.PubMedCentralPubMedCrossRef

65.

Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334(22):1422–7.PubMedCrossRef

66.

Asselah T, Lada O, Moucari R, Martinot M, Boyer N, Marcellin P. Interferon therapy for chronic hepatitis B. Clin Liver Dis. 2007;11(4):839–849 viii.PubMedCrossRef

67.

Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–95.PubMedCrossRef

68.

Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005;54(7):1009–13.PubMedCentralPubMedCrossRef

69.

Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992;102(6):2091–7.PubMed

70.

Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B: the Hepatitis Interventional Therapy Group. N Engl J Med. 1990;323(5):295–301.PubMedCrossRef

71.

Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56(5):699–705.PubMedCentralPubMedCrossRef

72.

Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206–17.PubMedCrossRef

73.

Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology. 1993;104(4):1116–21.PubMed

74.

Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995;109(3):908–16.PubMedCrossRef

75.

Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. 2012;56(5):1006–11.PubMedCrossRef

76.

Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013;58:872–80.PubMedCrossRef

77.

Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001–10.PubMedCrossRef

78.

Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011–20.PubMedCrossRef

79.

Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486–95.PubMedCrossRef

80.

Stranding DN, Seifer M, Patty A, Chapron C, Van Doorne LJ, Chao G, et al. HBV resistance determination from the telbivudine globe registration trial. J Hepatol. 2006;44:S191.CrossRef

81.

Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341(17):1256–63.PubMedCrossRef

82.

Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B: Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119(1):172–80.PubMedCrossRef

83.

Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33(6):1527–32.PubMedCrossRef

84.

Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125(6):1714–22.PubMedCrossRef

85.

Puchhammer-Stockl E, Mandl CW, Kletzmayr J, Holzmann H, Hofmann A, Aberle SW, et al. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis. 2000;181(6):2063–6.PubMedCrossRef

86.

Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antiviral Ther. 2009;14(8):1165–74.CrossRef

87.

Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–84.PubMedCrossRef

88.

Marcellin P, Martinot-Peignoux M, Lapalus M, Lada O, Ripault MP, Qian Z, et al. High rate of HBsAg loss predicted by baseline HBsAg titer and decline on treatment in chronic hepatitis B patients receiving pegylated interferon plus tenofovir combination therapy. Hepatology. 2011;54:254A.

89.

Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52(4):1251–7.PubMedCrossRef

90.

Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49(4):1151–7.PubMedCrossRef

91.

Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int. Epub 2011 Jun 28).

92.

Gane E, Jia J, Han K, Tanwandee T, Chuang WL, Marcellin P, et al. Neptune Study: on-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients. J Hepatol. 2011;54:S31.CrossRef

93.

Lampertico P, Vigano M, Galeota Lanza A, Sagenelli E, Fasano M, DiMarco V, et al. PegBeLiver Study: HBsAg decline at week 24 of extended peginterferon alfa-2a (peg-IFNα-2a) therapy is significantly associated with post-treatment response in HBeAg-negative genotype D patients. J Hepatol. 2011;54:S293.

94.

Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol. 2005;75(2):235–9.PubMedCrossRef

95.

Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol. 2011;54(3):449–54.PubMedCrossRef

96.

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. HBsAg kinetics in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 4 years. J Hepatol. 2011;54:740A.

97.

Wiegand J, Wedemeyer H, Finger A, Heidrich B, Rosenau J, Michel G, et al. A decline in hepatitis B virus surface antigen (HbsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels. Antiviral Ther. 2008;13(4):547–54.

Title: A Rationalized Approach to the Treatment of Patients Infected with Hepatitis B
Authors: Natravis R. Cox
Keyur Patel
Hans L. Tillmann
Publication date: 01-04-2014
Publisher: Springer International Publishing
Published in: Molecular Diagnosis & Therapy / Issue 2/2014
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI: https://doi.org/10.1007/s40291-013-0072-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A Rationalized Approach to the Treatment of Patients Infected with Hepatitis B

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

MicroRNA-499 rs3746444 Polymorphism and Autoimmune Diseases Risk: A Meta-Analysis

Association of E-Selectin Gene Polymorphism and Serum PAPP-A with Carotid Atherosclerosis in End-Stage Renal Disease

Sensitive Solid-Phase Detection of Donor-Specific Antibodies as an Aid Highly Relevant to Improving Allograft Outcomes

Comprehensive Profiling of EGFR/HER Receptors for Personalized Treatment of Gynecologic Cancers

Blood-Based Testing for Colorectal Cancer Screening

Utilizing Pharmacogenetics in Psychiatry: the Time Has Come

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page